Skip to main content

Homology Medicines, Inc. (FIXX)

NASDAQ: FIXX · Delayed Price · USD
6.05
-0.03 (-0.49%)
After-hours:Oct 21, 2021 5:37 PM EDT
6.08
0.00 (0.00%)
At close: Oct 21, 4:00 PM
Market Cap347.10M
Revenue (ttm)33.04M
Net Income (ttm)-89.60M
Shares Out56.50M
EPS (ttm)-1.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume514,636
Open6.10
Previous Close6.08
Day's Range5.99 - 6.16
52-Week Range5.94 - 15.24
Beta-0.45
AnalystsStrong Buy
Price Target23.00 (+278.3%)
Est. Earnings DateNov 8, 2021

About FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the live...

IndustryBiotechnology
Founded2015
CEOArthur Tzianabos
Employees205
Stock ExchangeNASDAQ
Ticker SymbolFIXX
Full Company Profile

Financial Performance

In 2020, FIXX's revenue was $2.70 million, an increase of 62.18% compared to the previous year's $1.67 million. Losses were -$128.69 million, 23.8% more than in 2019.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for FIXX stock is "Strong Buy." The 12-month stock price forecast is 23.00, which is an increase of 278.29% from the latest price.

Price Target
$23.00
(278.29% upside)
Analyst Consensus: Strong Buy

News

Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinic...

- Oral Presentation on In Vivo Gene Therapy Product Candidate and Data on Gene Editing Candidate Paved Way for Initiation of juMPStart and pheEDIT Trials -

1 day ago - GlobeNewsWire

Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults...

- juMPStart Trial to Evaluate First Systemic Gene Therapy Candidate for Patients with Hunter Syndrome -

3 days ago - GlobeNewsWire

Homology Medicines Announces World's First Gene Editing Clinical Trial for PKU

- IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing Approach -

1 week ago - GlobeNewsWire

Implied Volatility Surging for Homology Medicines (FIXX) Stock Options

Investors need to pay close attention to Homology Medicines (FIXX) stock based on the movements in the options market lately.

1 week ago - Zacks Investment Research

Homology Medicines (FIXX) Reports Q2 Loss, Tops Revenue Estimates

Homology Medicines (FIXX) delivered earnings and revenue surprises of 6.90% and 249.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Homology Medicines (FIXX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Homology Medicines (FIXX) Reports Q1 Loss, Tops Revenue Estimates

Homology Medicines (FIXX) delivered earnings and revenue surprises of 96.92% and 3681.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights

- On Track to Report Initial Phase 2 Data From pheNIX PKU Clinical Trial by Year End -

5 months ago - GlobeNewsWire

Will Homology Medicines (FIXX) Report Negative Q1 Earnings? What You Should Know

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting

- Data From Company's PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations -

6 months ago - GlobeNewsWire

Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer

- Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership -

6 months ago - GlobeNewsWire

Why Homology Medicines Stock Is Sinking Today

Dilution is on the way thanks to the company's latest stock offering.

6 months ago - The Motley Fool

Homology Medicines Announces Pricing of Public Offering of Common Stock

BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for...

6 months ago - GlobeNewsWire

Homology Medicines Announces Proposed Public Offering of Common Stock

BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subjec...

6 months ago - GlobeNewsWire

Homology Medicines (FIXX) Surges 5.9%: Is This an Indication of Further Gains?

Homology Medicines (FIXX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ...

6 months ago - Zacks Investment Research

Homology Medicines (FIXX) Reports Q4 Loss, Tops Revenue Estimates

Homology Medicines (FIXX) delivered earnings and revenue surprises of 4.62% and 130.59%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

- Phase 2 PKU Gene Therapy Trial Recruiting Patients With Initial Data Expected by Year End -

7 months ago - GlobeNewsWire

Earnings Preview: Homology Medicines (FIXX) Q4 Earnings Expected to Decline

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Homology Medicines Regains Global Rights To Novartis Ophthalmology Program

Homology Medicines Inc (NASDAQ: FIXX) has regained worldwide exclusive rights from Novartis AG (NYSE: NVS) to research, develop, manufacture, and commercialize its proprietary nuclease-free gene-editing...

Other symbols:NVS
7 months ago - Benzinga

Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing ...

- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication -

7 months ago - GlobeNewsWire

Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for H...

- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease -

8 months ago - GlobeNewsWire

Homology Medicines: $60 Million Pfizer Equity-Investment, 4 Encouraging Candidates, And Competent Management

Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeutic (HMI-102...

9 months ago - Seeking Alpha

Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates

Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.46% and 126.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights

- Based on Positive Data , Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase -

11 months ago - GlobeNewsWire

Homology Medicines News: 9 Things for FIXX Stock Investors to Know About the Pfizer Deal

Homology Medicines (FIXX) is making news on Monday after announcing a massive $60 million investment deal with Pfizer (PFE) The post Homology Medicines News: 9 Things for FIXX Stock Investors to Know Ab...

11 months ago - InvestorPlace